Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

Thymidylate Synthase Inhibition with Capped F10 Is Effective in TP53 Null Acute Myeloid Leukemia (AML)

Charles Okechukwu, Kristin Pladna, William Gmeiner, Timothy Pardee

Blood (2023) 142 (Supplement 1): 1430.

https://doi.org/10.1182/blood-2023-180057

Published: 2023

Journal Articles

Phase 1/2 First-in-Human Study of the Menin-MLL Inhibitor DSP-5336 in Patients with Relapsed or Refractory Acute Leukemia

Blood (2023) 142 (Supplement 1): 2911.

https://doi.org/10.1182/blood-2023-179252

Published: 2023

Journal Articles

Ongoing Phase III Randomized Trial of Salvage DFP-10917 Vs. Non-Intensive Reinduction or Intensive Reinduction for Acute Myelogenous Leukemia (AML)

Timothy Pardee, Michael Keng, Kiyoshi Eshima, Kenzo Iizuka, Chun Zhang

Blood (2023) 142 (Supplement 1): 5976.

https://doi.org/10.1182/blood-2023-190476

Published: 2023

Journal Articles

Acute Myeloid Leukemia (AML) from Older HSCs Is Resistant to Chemotherapy and Has an Altered DNA Damage Response

Kristin Pladna, Timothy Pardee

Blood (2023) 142 (Supplement 1): 5737.

https://doi.org/10.1182/blood-2023-190605

Published: 2023

Journal Articles

Complete Remission with Devimistat (CPI-613) in Refractory Burkitt Lymphoma

Liana Nikolaenko, Timothy Pardee, Raphel Steiner, Jeremy S. Abramson, Steven M. Horwitz, Matthew J. Matasar, Colette Owens, Ildefonso Rodriguez-Rivera, David J. Straus, Sanjeev Luther, Ariela Noy

Blood (2021) 138 (Supplement 1): 4555.

https://doi.org/10.1182/blood-2021-153662

Published: 2021

Journal Articles

Factors Affecting the Survival of Therapy Related AML/MDS, Secondary AML and De Novo AML

Rao Mushtaq, MD, Faisal Akbar, MBBS, MD, Israa Khan, MD, Scott Isom, M.S., Timothy Pardee, MD PhD, Dianna S. Howard, MD, Bayard L. Powell, MD

Blood (2018) 132 (Supplement 1): 5199.

https://doi.org/10.1182/blood-2018-99-110191

Published: 2018

Journal Articles

The Role of AMPK in Chemotherapy Response in AML

Lais P Ghiraldeli, MS, Rebecca G. Anderson, B.S., Kristin M. Pladna, M.S., Timothy Pardee, MD PhD

Blood (2018) 132 (Supplement 1): 2633.

https://doi.org/10.1182/blood-2018-99-119288

Published: 2018

Journal Articles

Therapeutic Manipulation of Cancer Cell Metabolism with the Mitochondrial Metabolism Inhibitor Cpi-613 in Addition to Chemotherapy Abrogates the Adverse Prognostic Effect of Age in Relapsed and Refractory AML

Timothy Pardee, MDPhD, Scott Isom, M.S., Leslie Renee Ellis, MD MSHPEd, Dianna S. Howard, MD, Rupali Bhave, MD, Megan Manuel, M.S.N, Sarah Dralle, M.S.N., Susan Lyerly, P.A.-C., Bayard L. Powell, MD

Blood (2018) 132 (Supplement 1): 1355.

https://doi.org/10.1182/blood-2018-99-118991

Published: 2018

Journal Articles

The Mitochondrial Metabolism Inhibitor Cpi-613 in Combination with High Dose Ara-C (HDAC) and Mitoxantrone Is Highly Active in Poor Risk Relapsed or Refractory Acute Myeloid Leukemia (AML)

Timothy Pardee, MD PhD, Kristin Pladna, MS, Scott Isom, MS, Leslie Renee Ellis, MD, Dmitriy Berenzon, MD, Dianna Howard, MD, Megan Manuel, MSN, Sarah Dralle, MSN, David D Hurd, MD, Susan Lyerly, PA-C, Bayard L Powell, MD

Blood (2015) 126 (23): 2556.

https://doi.org/10.1182/blood.V126.23.2556.2556

Published: 2015

Journal Articles

Feasibility of a Symptom-Adapted Physical Activity Intervention during Induction Chemotherapy for Older Adults with Acute Myeloid Leukemia (AML)

Heidi D. Klepin, MD MS, Janet Tooze, PhD, Timothy Pardee, MD PhD, Leslie Renee Ellis, MD, Dmitriy Berenzon, MD, Dianna Howard, MD, Wendy Demark-Wahnefried, PhD, Shannon Mihalko, PhD, William Jack Rejeski, PhD, Bayard L. Powell, MD, Stephen Kritchevsky, PhD

Blood (2015) 126 (23): 2102.

https://doi.org/10.1182/blood.V126.23.2102.2102

Published: 2015

Journal Articles

Adding KIT Inhibitor Dasatinib (DAS) to Chemotherapy Overcomes the Negative Impact of KIT Mutation/over-Expression in Core Binding Factor (CBF) Acute Myeloid Leukemia (AML): Results from CALGB 10801 (Alliance)

Guido Marcucci, MD, Susan Geyer, PhD, Weiqiang Zhao, MD PhD, Andrew J Caroll, PhD, Donna Bucci, Geoffrey L. Uy, MD, William Blum, MD, Timothy Pardee, MD PhD, Meir Wetzler, MD, Wendy Stock, MD, Jonathan E. Kolitz, MD, Ann-Kathrin Eisfeld, MD, Clara D. Bloomfield, MD, Richard M. Stone, MD, Richard A. Larson

Blood (2014) 124 (21): 8.

https://doi.org/10.1182/blood.V124.21.8.8

Published: 2014

Journal Articles

The Poison Oligonucleotide F10 Is Efficiently Taken Up By, and Highly Effective Against, Acute Lymphoblastic Leukemia While Sparing Normal Hematopoietic Cells

Timothy Pardee, MD, PhD, Jamie Jennings-Gee, PhD, Kristin Stadelman, MS, David L. Caudell, DVM, PhD, William Gmeiner, PhD

Blood (2013) 122 (21): 2674.

https://doi.org/10.1182/blood.V122.21.2674.2674

Published: 2013

Journal Articles

The Novel Phospholipid Gemcitabine Conjugate KPC34 Has Activity In Acute Leukemia

Timothy Pardee, MD, PhD, Peter Alexander, BA, Kristin Stadelman, MS, Greg Kucera, PhD

Blood (2013) 122 (21): 1425.

https://doi.org/10.1182/blood.V122.21.1425.1425

Published: 2013

Journal Articles

High Dose Cytarabine, Mitoxantrone and L-Asparaginase (HAMA) Salvage For Relapsed Or Refractory Acute Myeloid Leukemia (AML) In The Elderly

Tamjeed Ahmed, MD, Scott Holwerda, MD, Timothy Pardee, MD, PhD, Scott Isom, MS, Susan Lyerly, PA, Leslie Renee Ellis, MD, Megan Manuel, MSN, Sarah Dralle, MSN, Berenzon Dmitriy, MD, Heidi D. Klepin, MD, MS, Bayard L. Powell, MD

Blood (2013) 122 (21): 2700.

https://doi.org/10.1182/blood.V122.21.2700.2700

Published: 2013

Journal Articles

A Phase I Study Of The Safety, Efficacy and Pharmacokinetics Of The First In Class Pyruvate Dehydrogenase Complex Inhibitor Cpi-613 In Patients With Advanced Hematologic Malignancies

Timothy Pardee, MD, PhD, King Lee, PhD, RAC, John Luddy, MS, Claudia Maturo, MS, Robert Rodriguez, BSc, MBA, Denise A Levitan, MD, David D Hurd, MD, Leslie Renee Ellis, MD, Scott Isom, MS, Robin Harrelson, BSN, Megan Manuel, MSN, Sarah Dralle, MSN, Susan Lyerly, PA, Bayard L. Powell, MD

Blood (2013) 122 (21): 486.

https://doi.org/10.1182/blood.V122.21.486.486

Published: 2013

Journal Articles

Adding The KIT Inhibitor Dasatinib (DAS) To Standard Induction and Consolidation Therapy For Newly Diagnosed Patients (pts) With Core Binding Factor (CBF) Acute Myeloid Leukemia (AML): Initial Results Of The CALGB 10801 (Alliance) Study

Guido Marcucci, MD, Susan Geyer, PhD, John Zhao, MD, PhD, Andrew J Caroll, PhD, Donna Bucci, Ravi Vij, MD, William Blum, MD, Timothy Pardee, MD, PhD, Meir Wetzler, MD, Wendy Stock, MD, Clara D. Bloomfield, MD, Richard A. Larson, MD, Richard M. Stone, MD

Blood (2013) 122 (21): 357.

https://doi.org/10.1182/blood.V122.21.357.357

Published: 2013

Journal Articles

Thymidylate Synthase Inhibition with the Novel Fluoropyrimidine FdUMP[10] Is Highly Effective Against Acute Lymphoblastic Leukemia

Timothy Pardee, MD, PhD, Jamie Jennings-Gee, PhD, Peter Alexander, BA, William Gmeiner, PhD

Blood (2012) 120 (21): 1505.

https://doi.org/10.1182/blood.V120.21.1505.1505

Published: 2012

Journal Articles

The Novel Ribonucleotide Reductase Inhibitor Didox Is Active Against AML with Limited Toxicities

Guerry J Cook, MSc, David L. Caudell, DVM, PhD, Howard L Elford, PhD, Timothy Pardee, MD, PhD

Blood (2012) 120 (21): 1513.

https://doi.org/10.1182/blood.V120.21.1513.1513

Published: 2012

Journal Articles

Unique Dual Targeting of Thymidylate Synthase and Topoisomerase1 by FdUMP[10] Results in High Efficacy Against AML and Low Toxicity

Timothy Pardee, MD, PhD, Evan Gomes, PhD, Jamie Jennings-Gee, PhD, David L. Caudell, DVM, PhD, William Gmeiner, PhD

Blood (2011) 118 (21): 2584.

https://doi.org/10.1182/blood.V118.21.2584.2584

Published: 2011

Journal Articles

Over Expression of MN1 Accelerates Leukemia Onset and Confers Resistance to Chemotherapy by Suppression of p53 and Bim

Timothy Pardee, MD, PhD

Blood (2011) 118 (21): 2501.

https://doi.org/10.1182/blood.V118.21.2501.2501

Published: 2011

NARROW

Thymidylate Synthase Inhibition with Capped F10 Is Effective in TP53 Null Acute Myeloid Leukemia (AML)

Phase 1/2 First-in-Human Study of the Menin-MLL Inhibitor DSP-5336 in Patients with Relapsed or Refractory Acute Leukemia

Ongoing Phase III Randomized Trial of Salvage DFP-10917 Vs. Non-Intensive Reinduction or Intensive Reinduction for Acute Myelogenous Leukemia (AML)

Acute Myeloid Leukemia (AML) from Older HSCs Is Resistant to Chemotherapy and Has an Altered DNA Damage Response

Complete Remission with Devimistat (CPI-613) in Refractory Burkitt Lymphoma

Factors Affecting the Survival of Therapy Related AML/MDS, Secondary AML and De Novo AML

The Role of AMPK in Chemotherapy Response in AML

Therapeutic Manipulation of Cancer Cell Metabolism with the Mitochondrial Metabolism Inhibitor Cpi-613 in Addition to Chemotherapy Abrogates the Adverse Prognostic Effect of Age in Relapsed and Refractory AML

The Mitochondrial Metabolism Inhibitor Cpi-613 in Combination with High Dose Ara-C (HDAC) and Mitoxantrone Is Highly Active in Poor Risk Relapsed or Refractory Acute Myeloid Leukemia (AML)

Feasibility of a Symptom-Adapted Physical Activity Intervention during Induction Chemotherapy for Older Adults with Acute Myeloid Leukemia (AML)

Adding KIT Inhibitor Dasatinib (DAS) to Chemotherapy Overcomes the Negative Impact of KIT Mutation/over-Expression in Core Binding Factor (CBF) Acute Myeloid Leukemia (AML): Results from CALGB 10801 (Alliance)

The Poison Oligonucleotide F10 Is Efficiently Taken Up By, and Highly Effective Against, Acute Lymphoblastic Leukemia While Sparing Normal Hematopoietic Cells

The Novel Phospholipid Gemcitabine Conjugate KPC34 Has Activity In Acute Leukemia

High Dose Cytarabine, Mitoxantrone and L-Asparaginase (HAMA) Salvage For Relapsed Or Refractory Acute Myeloid Leukemia (AML) In The Elderly

A Phase I Study Of The Safety, Efficacy and Pharmacokinetics Of The First In Class Pyruvate Dehydrogenase Complex Inhibitor Cpi-613 In Patients With Advanced Hematologic Malignancies

Adding The KIT Inhibitor Dasatinib (DAS) To Standard Induction and Consolidation Therapy For Newly Diagnosed Patients (pts) With Core Binding Factor (CBF) Acute Myeloid Leukemia (AML): Initial Results Of The CALGB 10801 (Alliance) Study

Thymidylate Synthase Inhibition with the Novel Fluoropyrimidine FdUMP[10] Is Highly Effective Against Acute Lymphoblastic Leukemia

The Novel Ribonucleotide Reductase Inhibitor Didox Is Active Against AML with Limited Toxicities

Unique Dual Targeting of Thymidylate Synthase and Topoisomerase1 by FdUMP[10] Results in High Efficacy Against AML and Low Toxicity

Over Expression of MN1 Accelerates Leukemia Onset and Confers Resistance to Chemotherapy by Suppression of p53 and Bim

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only